Home>Topics>Stocks>Holly Energy Partners

Holly Energy Partners HEP

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Headlines
    1. The Hidden Side Of Sovaldi's Untapped Markets: Gilead's Rise Is Certain

      Headlines

      Mon, 30 Jun 2014

      relapse rate. Then came Gilead Sciences' ( GILD ) Sovaldi, which had relatively fewer side effects and the ability to eradicate Hep C 4 times faster than leading medications. Boosting Sovaldi's realized efficacy was that fact that the regimen involved taking

    2. Analyzing The Hepatitis C Market Size: Why It May Have Bullish Implications For Gilead

      Headlines

      Mon, 23 Jun 2014

      regimens to cure a form of viral hepatitis, namely hepatitis C (" hep C" herein). The two products that when combined in one treatment ..... Olysio with Sovaldi is expected to diminish when Gilead's next hep C blockbuster enters the market, likely in October. This is

    3. Sovaldi And Drug Pricing: The United States Of Saps

      Headlines

      Thu, 19 Jun 2014

      been rising in recent years on heightened expectations of the hep -C drug, and in the chart below one sees the increasing forward ..... there are enough well-insured (including by the government) hep -C patients to propel and sustain sales of all three companies

    4. What Is Next For The Hepatitis C Space?

      Headlines

      Fri, 13 Jun 2014

      hepatitis C market has come on investor's radar in a big way over the last few months. Gilead Sciences ( GILD ) launched its Hep C drug, Sovaldi, in the first quarter. The drug carries a huge price tag for its 12 week treatment program but cures what

    5. Conatus benefits from Hep C drug excitement

      Headlines

      Thu, 12 Jun 2014

      the rising tide of investor enthusiasm for hepatitis drugs led by the wildly successful launch of Gilead's ( GILD +0.2% ) Hep C treatment Sovaldi. Yesterday, shares popped 57% on a 19-fold surge in volume. The company's lead product is emricasan

    6. Oregon Health Plan says no to unlimited access to pricey Hep C drugs

      Headlines

      Thu, 12 Jun 2014

      becoming more and more popular among clinicians, costs $150,000 per regimen. Covering a third of the 7,000 OHP members with Hep C for Sovaldi alone ($84,000/regimen) would cost $196M. This would double its system-wide drug spending. Last year

    7. Achillion up in sympathy with Idenix deal

      Headlines

      Mon, 9 Jun 2014

      Pharmaceuticals ( ACHN ) are up 28% premarket on robust volume in response to the announcement of Merck's acquisition of rival Hep C firm Idenix Pharmaceuticals. The transaction bodes well for Achillion's attractiveness as an acquisition target. It has

    8. Merck buys Idenix

      Headlines

      Mon, 9 Jun 2014

      In an all-cash deal, M erck ( MRK ) acquires Hep C drug maker Idenix Pharmaceuticals ( IDIX ) for $24.50/share ($3.85B ). The company has an attractive portfolio of Hep C product candidates based on nucleotide/nucleoside chemistry and prodrug technologies. 4 comments!

    9. Medicare to pick up the cost of Hep C screening

      Headlines

      Tue, 3 Jun 2014

      wallet a bit further for cures like Sovaldi. As many as 2.7M Americans may be infected with the Hep C virus. Medicare will pay the cost of Hep C screening for high risk adults who inject or have injected illegal drugs or had a blood transfusion

    10. Orexigen Will Run: Here's Why

      Headlines

      Tue, 27 May 2014

      Congress wrote an open letter to John Martin the CEO of Gilead Sciences ( GILD ) questioning the price of Gilead's breakthrough Hep C drug Sovaldi . The letter caused Gilead's share price to drop over 10% and the ripple effect was felt by most biotech companies

    « Prev12345Next »
    Content Partners